[go: up one dir, main page]

NO20031806D0 - Anvendelse av pericytt apoptosehemmere for behandling og/eller forhindringav diabetisk retinopati - Google Patents

Anvendelse av pericytt apoptosehemmere for behandling og/eller forhindringav diabetisk retinopati

Info

Publication number
NO20031806D0
NO20031806D0 NO20031806A NO20031806A NO20031806D0 NO 20031806 D0 NO20031806 D0 NO 20031806D0 NO 20031806 A NO20031806 A NO 20031806A NO 20031806 A NO20031806 A NO 20031806A NO 20031806 D0 NO20031806 D0 NO 20031806D0
Authority
NO
Norway
Prior art keywords
pericytic
prevention
treatment
diabetic retinopathy
apoptosis inhibitors
Prior art date
Application number
NO20031806A
Other languages
English (en)
Inventor
Marc Lecomte
Ulriche Denis
Clarisse Paget
Nicolas Wiernsperger
Michel Lagarde
Original Assignee
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med filed Critical Inst Nat Sante Rech Med
Publication of NO20031806D0 publication Critical patent/NO20031806D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
NO20031806A 2000-10-24 2003-04-23 Anvendelse av pericytt apoptosehemmere for behandling og/eller forhindringav diabetisk retinopati NO20031806D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0013640A FR2815541B1 (fr) 2000-10-24 2000-10-24 Utilisation d'inhibiteurs de l'apoptose des pericytes pour le traitement et/ou la prevention de la retinopathie diabetique
PCT/FR2001/003306 WO2002034201A2 (fr) 2000-10-24 2001-10-24 Utilisation d'inhibiteurs de l'apoptose des pericytes pour le traitement et/ou la prevention de la retinopathie diabetique

Publications (1)

Publication Number Publication Date
NO20031806D0 true NO20031806D0 (no) 2003-04-23

Family

ID=8855696

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20031806A NO20031806D0 (no) 2000-10-24 2003-04-23 Anvendelse av pericytt apoptosehemmere for behandling og/eller forhindringav diabetisk retinopati

Country Status (9)

Country Link
US (1) US8119609B2 (no)
EP (2) EP1343491A2 (no)
JP (1) JP4387101B2 (no)
AU (1) AU2002214096A1 (no)
BR (1) BR0114759A (no)
CA (1) CA2428907A1 (no)
FR (1) FR2815541B1 (no)
NO (1) NO20031806D0 (no)
WO (1) WO2002034201A2 (no)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2815541B1 (fr) 2000-10-24 2008-02-29 Lipha Utilisation d'inhibiteurs de l'apoptose des pericytes pour le traitement et/ou la prevention de la retinopathie diabetique
WO2003061519A2 (en) * 2002-01-18 2003-07-31 Massachusetts Eye And Ear Infirmary Methods and compositions for preserving the viability of photoreceptor cells
JP4991297B2 (ja) * 2003-05-22 2012-08-01 キエジ ファルマチェウティチ エッセ・ピ・ア 細胞死を予防および治療するための手段およびそれらの生物学的適用
EP1740614A2 (en) * 2004-04-30 2007-01-10 Theraptosis S.A. Caspase-2 inhibitors and their biological applications
FR2878522B1 (fr) 2004-12-01 2008-04-18 Merck Sante Soc Par Actions Si Nouveaux inhibiteurs specifiques de la caspas-10
FR2884820B1 (fr) * 2005-04-25 2007-07-27 Merck Sante Soc Par Actions Si Nouveaux inhibiteurs specifiques de la caspase-10
WO2006123676A1 (ja) * 2005-05-17 2006-11-23 Santen Pharmaceutical Co., Ltd. 角結膜障害の予防または治療剤
US20070098709A1 (en) * 2005-06-29 2007-05-03 Gaetano Barile Methods for treating and preventing diabetic retinopathy
JP2010507387A (ja) 2006-10-25 2010-03-11 クアーク・ファーマスーティカルス、インコーポレイテッド 新規のｓｉＲＮＡおよびその使用方法
AU2008287285B2 (en) * 2007-04-13 2013-05-16 Southern Research Institute Anti-angiogenic agents and methods of use
ES2370751T3 (es) * 2007-05-25 2011-12-22 Santen Pharmaceutical Co., Ltd Agente profiláctico o terapéutico para la degeneración macular asociada a la edad.
RU2487716C2 (ru) 2007-10-03 2013-07-20 Кварк Фармасьютикалс, Инк. Новые структуры малых интерферирующих рнк (sirna)
US20110009376A1 (en) * 2008-02-28 2011-01-13 Shin-Ichiro Hirai Prophylactic or therapeutic agent for eye disease accompanied by optic nerve disorder
CA2741746C (en) * 2008-11-03 2016-08-23 Giuliani S.P.A. Therapeutic, dietary or cosmetic use of compounds with specific anti-apoptotic activity toward caspase-3, and compositions containing these compounds
PT2821405E (pt) * 2009-06-15 2016-06-14 Encore Health Llc Ésteres de colina para tratar a presbiopia e a catarata
TN2010000251A1 (fr) * 2010-06-03 2011-11-11 Rekik Raouf N-acetyl-dl-leucine medicament neuro et retino protecteur
JP2019520414A (ja) * 2016-07-11 2019-07-18 ザ トラスティーズ オブ コロンビア ユニバーシティ イン ザ シティ オブ ニューヨークＴｈｅ Ｔｒｕｓｔｅｅｓ Ｏｆ Ｃｏｌｕｍｂｉａ Ｕｎｉｖｅｒｓｉｔｙ Ｉｎ Ｔｈｅ Ｃｉｔｙ Ｏｆ Ｎｅｗ Ｙｏｒｋ 網膜浮腫を治療するための細胞膜透過性治療薬の眼内送達
WO2018085565A2 (en) * 2016-11-03 2018-05-11 Helix Biomedix, Inc. Short bioactive peptides blocking activity of advanced glycation end products, compositions, and methods of use
WO2019089993A1 (en) * 2017-11-02 2019-05-09 Living Cell Technologies New Zealand Limited Pericyte protective agents for neurological disorders including neurodegenerative diseases, central nervous system diseases and others
KR102366226B1 (ko) * 2019-05-31 2022-02-22 주식회사 엘지화학 캐스파제 저해제 프로드럭을 함유하는 주사용 조성물 및 이의 제조 방법
US10975169B1 (en) * 2019-09-27 2021-04-13 Memorial Sloan Kettering Cancer Center Methods for treating diabetic retinopathy using anti-ceramide monoclonal antibody 2A2

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0789951A (ja) * 1993-06-03 1995-04-04 Sterling Winthrop Inc インターロイキン−１β転換酵素阻害剤
US5731294A (en) * 1993-07-27 1998-03-24 Hybridon, Inc. Inhibition of neovasularization using VEGF-specific oligonucleotides
RU2070010C1 (ru) * 1993-08-31 1996-12-10 Эдуард Сергеевич Аветисов Средство антиоксидантной защиты сред и тканей глаза
US5714484A (en) * 1993-12-08 1998-02-03 Prototek, Inc. α-(1,3-dicarbonylenol ether) methyl ketones as cysteine protease inhibitors
WO1995017900A1 (en) * 1993-12-30 1995-07-06 Arcturus Pharmaceutical Corporation Methods for the treatment of the central nervous system or eye involving pathogenic oxidation pathways
US6013628A (en) * 1994-02-28 2000-01-11 Regents Of The University Of Minnesota Method for treating conditions of the eye using polypeptides
US5527533A (en) * 1994-10-27 1996-06-18 Board Of Trustees Of The University Of Illinois Method of retarding and ameliorating central nervous system and eye damage
JPH08175993A (ja) * 1994-12-21 1996-07-09 Green Cross Corp:The 抗酸化剤
JPH09278652A (ja) 1996-04-05 1997-10-28 Sumitomo Pharmaceut Co Ltd 網膜疾患治療剤
CA2280093A1 (en) * 1997-02-04 1998-08-06 John V. Kosbab Compositions and methods for prevention and treatment of vascular degenerative diseases
EP0971743B1 (de) * 1997-04-18 2006-07-12 Fritz Stanislaus Stabilisiertes arzneimittel enthaltend cysteinylderivate
WO1999002174A1 (en) * 1997-07-11 1999-01-21 Ludwig Institute For Cancer Research Non-human pdgf-b-deficient transgenic animals with reduced or non-existent numbers of pericytes
WO2000018392A1 (en) * 1998-09-25 2000-04-06 Glycox Corporation Limited Fructosamine oxidase: antagonists and inhibitors
US6242422B1 (en) * 1998-10-22 2001-06-05 Idun Pharmacueticals, Inc. (Substituted)Acyl dipeptidyl inhibitors of the ice/ced-3 family of cysteine proteases
AU2988200A (en) * 1999-02-11 2000-08-29 Trustees Of The University Of Pennsylvania, The Regulation of photoreceptor degeneration
DE19915465A1 (de) 1999-04-06 2000-10-19 Apotech Res & Dev Ltd Verwendung eines Caspase-Inhibitors zur Proliferationshemmung von Zellen und Verwendung eines oder mehrerer Caspase-Inhibitors/en zur Behandlung von Erkrankungen beruhend auf Lymphozyten-Hyperproliferation oder zur Suppression einer Immunantwort durch Lymphozyten
AU4213500A (en) * 1999-04-09 2000-11-14 Cytovia, Inc. Caspase inhibitors and the use thereof
US6288106B1 (en) * 1999-05-25 2001-09-11 Chronorx, Llc Processes for the synthesis and use of various α-lipoic acid complexes
AU5601300A (en) * 1999-06-09 2000-12-28 Department Of The Army, U.S. Government Method and compositions for treating and preventing retinal damage
US6103756A (en) * 1999-08-11 2000-08-15 Vitacost Inc. Ocular orally ingested composition for prevention and treatment of individuals
AU1920501A (en) * 1999-12-03 2001-06-12 Alcon Universal Limited The use of caspase 9 inhibitors to treat ocular neural pathology
US6800619B2 (en) * 2000-09-13 2004-10-05 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
US20020086007A1 (en) * 2000-10-13 2002-07-04 Sim Kim Lee Angiogenesis-inhibiting peptides and proteins and methods of use
FR2815541B1 (fr) 2000-10-24 2008-02-29 Lipha Utilisation d'inhibiteurs de l'apoptose des pericytes pour le traitement et/ou la prevention de la retinopathie diabetique

Also Published As

Publication number Publication date
JP4387101B2 (ja) 2009-12-16
FR2815541B1 (fr) 2008-02-29
JP2004512287A (ja) 2004-04-22
US20030216290A1 (en) 2003-11-20
EP1343491A2 (fr) 2003-09-17
EP2359840A1 (fr) 2011-08-24
FR2815541A1 (fr) 2002-04-26
US8119609B2 (en) 2012-02-21
WO2002034201A3 (fr) 2003-03-27
CA2428907A1 (fr) 2002-05-02
BR0114759A (pt) 2003-10-07
WO2002034201A2 (fr) 2002-05-02
AU2002214096A1 (en) 2002-05-06

Similar Documents

Publication Publication Date Title
NO20031806D0 (no) Anvendelse av pericytt apoptosehemmere for behandling og/eller forhindringav diabetisk retinopati
DK1487541T3 (da) Anvendelse af IL-18-inhibitorer til behandling og/eller forebyggelse af perifere vaskulære sygdomme
NO20044272L (no) Legemiddel for behandling og/eller forebyggelse av kronisk avstotning
EE200300475A (et) Türosiini kinaasi inhibiitorid, neid sisaldavad ravimkoostised ja nimetatud ühendid kasutamiseks haiguste ravis
NO20034430D0 (no) Tiohydantoiner og anvendelse derav for behandling av diatbetes
NO20025307D0 (no) Anvendelse av IL-18 inhibitorer til behandling og/eller forebygging av aterosklerose
CL2004001174A1 (es) Composicion farmaceutica que comprende: 1-(4-fluorofenil)-3(r)-[3-(4-fluorofenil)-3(s)-hidroxipropil]-4(s)-(4-hidroxifenil)-2-acetidinona (ezetimiba) y excipientes; y su uso en el tratamiento y/o prevencion de aterosclerosis, hipercolesterolemia, dia
IS6560A (is) Lyfjasamsetning fyrir meðhöndlun á bráðum, þrálátum sársauka og/eða taugakerfissársauka og mígreni
DK1309324T3 (da) Antikonvulsive derivater egnede til behandling og forebyggelse af udvikling af type II diabetes mellitus og syndrom X
IS6934A (is) Nýjar spírótrísýklískar afleiður og notkun þeirrasem fosfódíesterasa-7-hindrar
EP1274444A4 (en) COMPOUNDS FOR THE TREATMENT OF PSYCHIATRIC DISORDERS OR DISORDERS CAUSED BY THE ABUSE OF PSYCHOACTIVE SUBSTANCES
NO20044195L (no) Biofosfoninsyrer for behandling og prevensjon av osteoprose
NO20021784D0 (no) Anvendelse av dipyridamol eller mopidamol for fremstilling av et medikament for behandling og forebygging av fibrin-avhengigmikrosirkulasjonsforstyrrelser
NO20052009D0 (no) Kombinasjonsterapi for behandling av akutt leukumi og myelodysplastikksyndrom
NO20041214L (no) Substituerte benzimidazolforbindelser og deres anvendelse for behandling av cancer
NO20033443D0 (no) Anvendelse av CD-2-bindende midler ved behandling eller forebygging av hudlidelser
IS6966A (is) Cýanó-tengd díhýdrópýrimídín efnasambönd og notkun þeirra við meðhöndlun sjúkdóma
NO20034300L (no) Nye cyano-substituerte dihydropyrimidinforbindelser og anvendelse for behandling av sykdommer
DK1355668T3 (da) Anvendelse af IL-18 inhibitorer til behandling og/eller forebyggelsen af hjertesygdom
NO20054913D0 (no) Anvendelse av clustein for behandling og/eller forebyggelse av perifere nevrologiske lidelser
PT1274700E (pt) Di-hidrobenzopiranos di-hidrobenzotiopiranos e tetra-hidroquinolinas para o tratamento de afeccoes mediadas por cox-2
DK1562577T3 (da) Acetyl-L-carnitin til forebyggelse og/eller behandling af perifere neuropatier, der induceres af anticancermidler
DE60233740D1 (de) Benzoägüchinolinderivate zur behandlung von glaucom und kurzsichtigkeit
NO20004920D0 (no) Anvendelse av proteaseinhibitorer for behandling av hudskader
NO20030811D0 (no) Kromenonderivater og anvendelse derav til behandling av sykdommer i forbindelse med 5-HTA1-reseptorer og/eller dopamin-D2-reseptorer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application